• Liver cancer (Hepatocellular carcinoma, HCC) is the second leading cause of cancer death in men and ninth in women. There were over 780,000 new cases worldwide with 50% of total accounted in China. (American Cancer Society, 2015)
• At present, there are only a few molecular targeted therapies for HCC patients, and anti-DKK1 antibody has not been considered for treating HCC, which may be a potential therapy and additional option for HCC patients.
• Data showed that DKK1 enhanced growth of HCC cells in vivo.

• In vitro test on HCC cell lines showed that anti-DKK1 antibody is able to suppress cell migration of HCC cells.
• In vivo test on mice demonstrated the suppressive effect of anti-DKK1 monoclonal antibody on the growth of HCC tumor.
• Data shows that serum levels of DKK1 could serve as a prognosis of HCC for patients.
• Figure 1: Anti-DKK1 antibody was able to inhibit the migration of cell when compared to the control group.
• Figure 2: Tumor size and mass in mice decreased when injected with DKK1 antibody, indicating that anti-DKK1 antibody is able to suppress tumor growth.

• Anti-DKK1 antibody as treatment for HCC patients
• Anti-DKK1 antibody against cancer metastasis in HCC patients

Patents

• US Patent Application No. 13/361,439;
• Chinese Patent No. ZL201280016543.1 issued on 13 Apr 2016;
• EP Patent No. 2670435 issued on 23 Aug 2017

IP Status

• Patented
• Patent application submitted